IGM Biosciences (NASDAQ:IGMS) Shares Down 6.5% Following Analyst Downgrade

IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating)’s share price traded down 6.5% during mid-day trading on Tuesday after Guggenheim lowered their price target on the stock from $40.00 to $38.00. The company traded as low as $12.84 and last traded at $12.89. 52,848 shares were traded during mid-day trading, a decline of 76% from the […]

Related Keywords

Canada ,Blackrock ,Nova Scotia ,Chrish Takimoto , ,Pricet Rowe Associates Inc ,Biosciences Inc ,Biosciences Company Profile ,Igm Biosciences Inc ,Jpmorgan Chase Co ,Millennium Management ,Blackrock Inc ,Morgan Stanley ,Nasdaq ,Royal Bank ,Vanguard Group Inc ,Get Rating ,Digm Biosciences ,Nasdaq Igms ,Igms ,Medical ,Stocks ,Technicals ,